elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q36868056-A1B7DA4B-FC25-43C9-96CF-0C9454D7E9A2
Q36868056-A1B7DA4B-FC25-43C9-96CF-0C9454D7E9A2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36868056-A1B7DA4B-FC25-43C9-96CF-0C9454D7E9A2
Bortezomib for the treatment of non-Hodgkin's lymphoma
P2860
Q36868056-A1B7DA4B-FC25-43C9-96CF-0C9454D7E9A2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36868056-A1B7DA4B-FC25-43C9-96CF-0C9454D7E9A2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
582318dc37bfebc7604887a078a62842aaf1e2a5
P2860
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.